ClassID:

20399

A61K31/4743 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom; Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom

Recent Application in this class:
#1
20250382306
2025-12-18

HETEROCYCLIC COMPOUND AS TAAR1 LIGAND AGONIST

#2
20250367212
2025-12-04

PHARMACOTHERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES

#3
20250154105
2025-05-15

POLYCYCLIC COMPOUND AND USE THEREOF

#4
20250066349
2025-02-27

CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

#5
20240254118
2024-08-01

PRMT5 INHIBITORS AND USES THEREOF

#6
20240228504
2024-07-11

SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME

#7
20240199634
2024-06-20

CYCLIC COMPOUNDS AND METHODS OF USING SAME

#8
20230108906
2023-04-06

SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME

#9
20230042367
2023-02-09

METHODS AND COMPOSITIONS FOR TREATING CANCERS HAVING F-BOX AND WD-REPEAT PROTEIN 7 (FBXW7) ALTERATIONS AND/OR CYCLIN L1 (CCNL1) GAIN OR AMPLIFICATION

#10
20220125818
2022-04-28

COMPOSITIONS AND METHODS FOR TREATMENT OF A CORONAVIRUS DISEASE (COVID-19) INFECTION

#11
20220073647
2022-03-10

APPLICATION OF PCSK9 INHIBITORS IN THE PREPARATION OF DRUGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES

#12
20200276181
2020-09-03

THIENOISOQUINOLINES AND THEIR DERIVATIVES FOR TARGETING TUBULIN, CH-TOG, AURORA A KINASE, TPX2, CDK5RAP2 AND/OR ASPM

#13
20200197325
2020-06-25

METHODS INVOLVING DOWNREGULATING APOBEC3B

#14
20190022100
2019-01-24

ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF

#15
20180312607
2018-11-01

Application of PCSK9 inhibitors in the preparation of drugs for the treatment of inflammatory immune diseases

#16
20180298020
2018-10-18

Piperidine derivative and preparation method and pharmaceutical use thereof

#17
20180185302
2018-07-05

METHODS FOR DOWNREGULATING APOBEC3B

#18
20180153889
2018-06-07

MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES

#19
20180093997
2018-04-05

Use of physiological cooling active ingredients, and agents containing such active ingredients

#20
20170096636
2017-04-06

METHODS AND COMPOUNDS FOR PHOTOTHERAPY WITH CHALCOGENORHODAMINE PHOTOSENSITIZERS

#21
20170079972
2017-03-23

ROS1 inhibitor and its use

#22
20170065587
2017-03-09

Antiviral axin stabilizer

#23
20170037054
2017-02-09

Method for preparing spherical Clopidogrel Hydrogen Sulfate polymorph I

#24
20160318948
2016-11-03

Compounds inhibiting eukaryotic elongation factor 2 kinase activity

#25
20160129006
2016-05-12

Antiviral compounds and methods of use thereof

#26
20150274713
2015-10-01

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

#27
20150086491
2015-03-26

Use of physiological cooling active ingredients, and agents containing such active ingredients

#28
20140303201
2014-10-09

Cancer therapy

#29
20140243524
2014-08-28

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

#30
20140128383
2014-05-08

Inhibitors of viral replication, their process of preparation and their therapeutical uses

#31
20130071353
2013-03-21

Antiviral compounds and methods of use thereof

#32
20130005965
2013-01-03

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

#33
20120263659
2012-10-18

Use of physiological cooling active ingredients, and agents containing such active ingredients

#34
20120004256
2012-01-05

Parenteral formulation of clopidogrel

#35
20110306632
2011-12-15

Solid dispersions containing kinase inhibitors

#36
20110269792
2011-11-03

COMPOSITIONS USEFUL FOR TREATING IRRITABLE BOWEL SYNDROME

#37
20110039879
2011-02-17

METHODS FOR INCREASING WHITE BLOOD CELLS

#38
20110033474
2011-02-10

INHIBITION OF PLATELET AGGREGATION

#39
20110028420
2011-02-03

Regression of Established Atherosclerotic Plaques, and Treating Sudden-Onset Asthma Attacks, using PARP Inhibitors

#40
20100256112
2010-10-07

Hydroxylthienoquinolones and related compounds as anti-infective agents

#41
20100210679
2010-08-19

PREVENTIVE AND THERAPEUTIC MEDICAMENT FOR GASTROESOPHAGEAL REFLUX DISEASE

#42
20100204267
2010-08-12

Preventive and therapeutic medicament for gastroesophageal reflux disease

#43
20100197922
2010-08-05

Azabicycloalkane compounds

#44
20100168157
2010-07-01

PREVENTIVE AND THERAPEUTIC MEDICAMENT FOR GASTROESOPHAGEAL REFLUX DISEASE

#45
20100152231
2010-06-17

Compositions Useful For Treating Irritable Bowel Syndrome

#46
20100105637
2010-04-29

Drug-surfactant complexes for sustained release

#47
20100099672
2010-04-22

METHODS FOR TREATING HEPATITIS C

#48
20100069371
2010-03-18

Thienopyridine and furopyridine kinase inhibitors

#49
20100056564
2010-03-04

Association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent

#50
20090253906
2009-10-08

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

#51
20090214602
2009-08-27

Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor

#52
20090048443
2009-02-19

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

#53
20090042930
2009-02-12

PHARMACEUTICAL COMPOSITIONS CONTAINING CLOPIDOGREL BISULFATE

#54
20090036411
2009-02-05

MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES

#55
20090018137
2009-01-15

Modulation of cell fates and activities by phthalazinediones

#56
20080293762
2008-11-27

Preventive and Therapeutic medicament for gastroesophageal reflux disease

#57
20080269276
2008-10-30

COMPOSITIONS USEFUL FOR TREATING IRRITABLE BOWEL SYNDROME

#58
20080262016
2008-10-23

ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF

#59
20080139603
2008-06-12

Azabicycloalkane compounds

#60
20080113934
2008-05-15

USE OF DIPYRIDAMOLE OR MOPIDAMOL FOR TREATMENT AND PREVENTION OF FIBRIN-DEPENDENT MICROCIRCULATION DISORDERS

#61
20080103207
2008-05-01

TOPICAL CERAMIDE COMPOSITIONS AND METHODS OF USE

#62
20080070841
2008-03-20

Use of SERP-1 as an antiplatelet agent

#63
20080069738
2008-03-20

Selective resonant reconfiguration of chemical structures

#64
20070243243
2007-10-18

Oral dosage forms including an antiplatelet agent and an acid inhibitor

#65
20070185065
2007-08-09

Combination therapy for coronary artery disease

#66
20070155776
2007-07-05

Thienopyridine and furopyridine kinase inhibitors

#67
20070142303
2007-06-21

Modulation of cell fates and activities by phthalazinediones

#68
20070054934
2007-03-08

Association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent

#69
20070042041
2007-02-22

Drug-surfactant complexes for sustained release

#70
20070021458
2007-01-25

Selective resonance of bodily agents

#71
20070010543
2007-01-11

Compositions and methods for treating gastrointestinal hypomotility and associated disorders

#72
20070003615
2007-01-04

Nanoparticulate clopidogrel and aspirin combination formulations

#73
20060281781
2006-12-14

Preventive and therapeutic medicament for gastroesophageal reflux disease

#74
20060281769
2006-12-14

SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS

#75
20060276486
2006-12-07

Lklf/klf2 gene expression promoter

#76
20060258699
2006-11-16

Compounds for inhibiting KSP kinesin activity

#77
20060217351
2006-09-28

Method for treating cardiovascular diseases

#78
20060205764
2006-09-14

Inhibition of platelet aggregation

#79
20060199807
2006-09-07

Use of N-desmethylclozapine to treat human neuropsychia tric disease

#80
20060194831
2006-08-31

Use of N-desmethylclozapine to treat human neuropsychiatric disease

#81
20060183921
2006-08-17

Pharmaceutically active compounds and methods of use

#82
20060122115
2006-06-08

Use of SERP-1 as an antiplatelet agent

#83
20060079548
2006-04-13

Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use

#84
20060074102
2006-04-06

Kinase inhibitors as therapeutic agents

#85
20060063766
2006-03-23

Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin

#86
20060052378
2006-03-09

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

#87
20060051319
2006-03-09

Neuroprotective effect of solubilized UDCA in focal ischemic model

#88
20060019976
2006-01-26

Methods for treating hepatitis C

#89
20050288291
2005-12-29

Modulation of cell fates and activities by phthalazinediones

#90
20050282852
2005-12-22

Preventive and therapeutic medicament for gastroesophageal reflux disease

#91
20050256152
2005-11-17

Salt of a sulfonic acid containing clopidogrel and use thereof for the production of pharmaceutical formulations

#92
20050250767
2005-11-10

Use of N-desmethylclozapine to treat human neuropsychiatric disease

#93
20050203122
2005-09-15

Benzenesulfonic acid salts of clopidogrel, methods for preparing same, and pharmaceutical formulations thereof

#94
20050192245
2005-09-01

Medicinal composition for treating arteriosclerosis

#95
20050148562
2005-07-07

Pharmaceutical compositions based on anticholinergics and additional active ingredients

#96
20050049275
2005-03-03

Racemization and enantiomer separation of clopidogrel

#97
20050043347
2005-02-24

Thienopyridine and furopyridine kinase inhibitors

#98
20050020694
2005-01-27

Sulfide and disulfide compounds and compositions for cholesterol management and related uses